NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, these results indicate that NFκB/IKK is essential for BCR-ABL—induced cell growth and survival and that the kinase IKKβ represents an attractive therapeutic target in CML.